Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis.

BACKGROUND: We have performed this study to evaluate the association between H19 rs217727 polymorphism and the risk of cancer. METHODS: An odds ratio (OR) with a 95% confidence interval (CI) was applied to determine a potential association. RESULTS: A total of 17 case-control publications were selected. This meta-analysis showed that H19 rs217727 has a significant increased association with cancer risk in allelic, homozygous, heterozygote, dominant and recessive models (T vs C: OR = 1.16, 95% CI = 1.06-1.27, I2 = 75.7; TT vs CC: OR = 1.29, 95% CI = 1.06-1.56, I2 = 71.6; CT vs CC: OR = 1.15, 95% CI = 1.01-1.31, I2 = 75.4; CT + TT vs CC: OR = 1.20, 95% CI = 1.05-1.36, I2 = 76.5; TT vs CT + CC: OR = 1.22, 95% CI = 1.02-1.45, I2 = 70.6;). In the subgroup analysis of smoking status, both smokers and nonsmokers showed an increase in cancer risk in allelic, homozygous, dominant and heterozygote models. CONCLUSION: This meta-analysis revealed H19 rs217727 may influence cancer susceptibility.

Clinicopathological and prognostic significance of zinc finger antisense 1 overexpression in cancers: A meta-analysis.

BACKGROUND: An increasing number of studies have recently highlighted the role of zinc finger antisense 1(ZFAS1) as a prognostic marker in cancers. However, these results remain controversial. Hence, a meta-analysis was conducted to further investigate the effects of ZFAS1 expression on clinicopathological features and survival outcomes. METHOD: All eligible studies were searched from PubMed, Embase, Web of Science, and the Cochrane Library. All included articles evaluated the relationship between the expression levels of ZFAS1 and survival, or the range of pathological features in cancer patients. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were computed to evaluate the effect of ZFAS1 expression on overall survival (OS), relapse-free survival (RFS), and disease-free survival (DFS). The relationship between ZFAS1 expression and clinicopathological features was determined through pooled odds ratios (ORs) and 95% CIs. RESULTS: In total 8 studies, which comprised of 820 patients, were qualified for analysis. Results revealed that the overexpression of ZFAS1 was significantly associated with poor OS (HR = 1.97, 95% CI: 1.53-2.54), worse RFS (HR = 1.95, 95% CI: 1.24-3.04) and worse DFS (HR = 2.35, 95% CI: 1.43-3.88) in cancers. Further subgroup analysis revealed that ZFAS1 overexpression was significantly correlated with poor OS in different cancer types, HR obtain methods and sample sizes. In addition, this meta-analysis revealed that the upregulated expression of ZFAS1 was significantly associated with lymph node metastasis, Tumor Node Metastasis (TNM) stage, and tumor size. CONCLUSIONS: This meta-analysis revealed that the expression of ZFAS1 was associated with tumor prognosis. ZFAS1 could be used as a predictor for tumor progression in various cancers.